High Gal-3 expression in several cancers has been suggested to predict a poor response to immune checkpoint therapy with the anti-PD-1 monoclonal antibody pembrolizumab, including human lung adenocarcinoma and melanoma patients (11, 23). Here, PDCD1 is linked to melanoma.